Advancing Care in Prostate Cancer: Evolving Standards of Care Throughout the Disease Continuum

Sunday, June 3, 2018-Attend this live symposium in Chicago to gain expert perspectives on new changes in prostate cancer treatment!

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

Radisson Blu Aqua Hotel
bus route 11

Route 11 - Gate 31: East Bldg, Level 2, near Arie Crown Theater Box Office
One-way travel time is approximately 12-15 minutes.


Welcome and Program Overview
Oliver Sartor, MD Program Director

Case Discussion 1: Optimizing Treatment in the Nonmetastatic Setting
Michael J. Morris, MD

Case Discussion 2: Optimizing Treatment in the Metastatic Setting
Oliver Sartor, MD

Predictive Biomarkers and Future Directions in Prostate Cancer
Charles J. Ryan, MD


Date / Time
Event Details


Program Chair
Oliver Sartor, MD

C.E. and Bernadine Laborde Professor of Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana

Michael J. Morris, MD

Associate Professor
Prostate Cancer Section Head
Clinical Director

GU Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Charles J. Ryan, MD

Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
 Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Program Overview
The primary purpose of this program is to ensure that clinicians have the most current findings and expert perspectives to improve outcomes for their patients with prostate cancer. The program consists of a 2-hour live symposium and associated enduring online education.

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in applying evolving clinical evidence and expert guidance to individualize treatment choices for patients with prostate cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with prostate cancer.

Learning Objectives

  • Effectively determine individualized treatment plans for patients with prostate cancer using the latest agents in appropriate sequences or combinations in accordance with up-to-date evidence and expert recommendations throughout the disease continuum
  • Evaluate recent practice-changing clinical trial findings concerning novel compounds or strategies to manage castration-resistant prostate cancer, including hormone, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies alone and in combination, to safely and effectively integrate them into care
  • Refer appropriate patients with prostate cancer to ongoing clinical trials of assessing novel therapies alone and in combination throughout the disease continuum to aid in trial enrollment


Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Clinical Care Options, LLC. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Purdue University College of Pharmacy designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
All faculty, staff, and reviewers involved in the planning, review, or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.